The next generation of obesity and diabetes trials are being run out of Australia. Sponsors who once defaulted to the US or Europe are increasingly choosing us. The question worth asking is why.
The short answer is capability. At Clinibase, a Melbourne scale-up working across clinical trials in Australia and New Zealand, we are seeing it firsthand. Enquiries for these cardiometabolic studies have surged, with sponsors bringing programs that would once have gone elsewhere. What they are looking for is not just speed. They are looking for sites with the scientific depth and operational capabilities to run studies that are genuinely hard to run well.
Clinical trials are how new medicines move from hypothesis to prescription. Australia’s sector contributes $1.6 billion to the economy annually and cardiometabolic trials is now one of its fastest-growing frontiers. The sponsors choosing to run these programs here are not just bringing scientific opportunity. They are bringing investment, jobs and the kind of long-term partnerships that build industries.
The drugs at the centre of this activity represent a genuine leap forward. Current GLP-1 therapies have already transformed obesity medicine, delivering weight loss results that were once considered impossible without surgery. The next generation goes further, with several being developed as daily tablets rather than weekly injections, a shift that could dramatically expand who can access them and how widely they are used.
Many are designed to specifically target fat loss while reducing muscle mass loss, addressing a common side effect of rapid weight reduction. Yet others are shifting from simple weight loss to comprehensive cardiometabolic protection, offering greater efficacy in reducing heart failure, kidney disease, and liver fat.
Most programs are still in early phases, but the pipeline is substantial and the investment behind it is serious. Obesity and cardiometabolic therapeutic areas were among the most active areas for biotech investment and dealmaking globally in 2025, second only to oncology. That capital is chasing quality clinical trial capacity and it is increasingly finding it here.
Australia’s case to host this research is built on more than regulatory speed and tax incentives, though both matter. The TGA’s Clinical Trial Notification pathway means studies commence in weeks. The 43.5% R&D tax incentive returns capital at the stage sponsors are burning through it fastest. But underneath those advantages is something harder to replicate: a diverse, engaged population that understands cardiometabolic conditions firsthand. GLP-1 prescriptions in Australia have grown nearly tenfold in five years.
Awareness is high, engagement with the healthcare system is strong, and recruitment into cardiometabolic trials reflects that. For sponsors running intensive monitoring protocols – regular site visits, blood tests, cardiometabolic tracking – participant retention is everything. Australian sites deliver it.
The Australians participating in these trials are people who have lived with obesity or type 2 diabetes for years, who understand what is at stake, and who are making an active choice to be part of finding something better. That motivation shows up in retention rates, in the quality of data collected, and in the trust that builds between participants and sites over the course of a study. It is not something you can manufacture with a recruitment campaign. It is the product of a healthcare system that has spent years taking cardiometabolic disease seriously.
What is less often articulated and what I find myself explaining to sponsors regularly, is the depth of scientific and operational capability sitting behind those structural advantages. The clinical teams, the trial sites, the trial infrastructure have been built over years of running early- and late-phase programs. They are not easy to replicate quickly, and sponsors bringing next-generation programs know the difference between a site that can meet those demands and one that cannot.
Australia is not a default choice for these programs. It is a deliberate one. Other markets are waking up to the same opportunity: Singapore is expanding early-phase capacity, the UK is streamlining its research environment. The window is open, but it will not stay that way indefinitely.
We are at an early stage of what could become a defining moment for Australian cardiometabolic research. The sponsors are here, the science is ready, and the capability exists. What’s needed now is the intention to make the most of it before the moment passes to somewhere else.
Pam Ramali is the chief executive officer of Clinibase, which partners with biotech and pharmaceutical companies, research organisations, and clinical sites to streamline early-phase and late-phase trials and improve participant experience. Clinibase is Australia’s largest full-service clinical trial recruitment provider.
Do you know more? Contact James Riley via Email.